Payal Kohli, MD, FACC

Panelists discuss how the endothelin pathway critically regulates blood pressure and vascular health through the interplay between vasodilators and vasoconstrictors such as endothelin-1, representing a key mechanism in hypertension pathophysiology.

Panelists discuss how resistant hypertension management requires a structured approach combining lifestyle modifications, optimal doses of multiple drug classes, and the identification of underlying causes such as sleep apnea.

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Panelists discuss how traditional antihypertensive medications face challenges including adverse reactions, complex dosing regimens, and variable efficacy across different patient populations, which can limit their therapeutic success.

Panelists discuss how poor medication adherence and comorbidities such as chronic kidney disease (CKD) contribute to uncontrolled hypertension despite the availability of numerous treatment options, highlighting key challenges in achieving effective blood pressure management.

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.

Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients

Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.

Expert cardiologists discuss if there is such a thing as an LDL that is a too low.

Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.

Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.

A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.

The reasons many patients do not reach LDL-cholesterol thresholds.

Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.

Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.